Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 71

Sort by

Sort Order Select

Journal Articles

Primary Results from the Phase 3 Tourmaline-AL1 Trial of Ixazomib-Dexamethasone Versus Physician's Choice of Therapy in Patients (Pts) with Relapsed/Refractory Primary Systemic AL Amyloidosis (RRAL)

Angela Dispenzieri, MD, Eftathios Kastritis, Ashutosh D Wechalekar, MB BS, MD FRCP, FRCPath, DM, Stefan O. Schönland, MD, Kihyun Kim, MD, Vaishali Sanchorawala, MD, Heather J Landau, MD, Fiona Kwok, FRACP,FRCPA,MBBS, Kenshi Suzuki, MD PhD, Raymond L Comenzo, MD, Deborah Berg, RN, MSN, Guohui Liu, PhD, Douglas V. Faller, MD PhD, Giampaolo Merlini, MD

Blood (2019) 134 (Supplement_1): 139.

https://doi.org/10.1182/blood-2019-124409

Published: 2019

Journal Articles

Localized Pulmonary Amyloidosis: A Single Institution Experience

Ajay Tambe, MBBS, Poornima Ramadas, MBBS, Mijung Lee, MD, Kanish Mirchia, MD

Blood (2019) 134 (Supplement_1): 5464.

https://doi.org/10.1182/blood-2019-125124

Published: 2019

Journal Articles

Another Obesity Paradox: In Cardiac AL Amyloid a Higher BMI Is Associated with a Lower Rate of Cardiac Response

So Yeon Kim, MD, Amanda Vest, MD, Raymond L Comenzo, MD, Cindy Varga, MD BSc

Blood (2019) 134 (Supplement_1): 5502.

https://doi.org/10.1182/blood-2019-123890

Published: 2019

Journal Articles

In Vitro and in Vivo Activity of Melflufen in Amyloidosis

Ken Flanagan, PhD, Muntasir M Majumder, MSc, BPharm, Romika Kumari, PhD, Juho Miettinen, PhD, Ana Slipicevic, PhD, Sarah A. Holstein, MD PhD, Michelle L. Varney, MS, Minna Suvela, MSC, Fredrik Lehmann, PhD, Nina N. Nupponen, PhD, Caroline A Heckman, PhD

Blood (2019) 134 (Supplement_1): 3100.

https://doi.org/10.1182/blood-2019-125952

Published: 2019

Journal Articles

β 2 -m - a Trigger for NLRP3 Inflammasome Activation within Macrophages Promoting Multiple Myeloma Cell Proliferation

Daniel Hofbauer, Dimitrios Mougiakakos, MD, Maike Büttner-Herold, Frank Neumann, PhD, Jens Nolting, Savita Bisht, Robert Zeiser, MD, Shaima'A Hamarsheh, MSc,BSc, Stefano Ricagno, PhD, Mario Zaiss, Martin Eberhardt, Martin Boettcher, PhD, Katrin Bitterer, Andreas Mackensen, MD, Heiko Bruns, PhD

Blood (2019) 134 (Supplement_1): 2314.

https://doi.org/10.1182/blood-2019-123958

Published: 2019

Journal Articles

A Phase 1 Study of Carfilzomib-Thalidomide-Dexamethasone in Patients with Relapsed/Refractory AL Amyloidosis - Catalyst Trial Results

Mamta Garg, MD FRCP, FRCPath, Andrew Hall, Matthew Jenner, MBBS, MRCP, FRCPath, Bhuvan Kishore, MB BS, MRCP, FRCPath, Helen J Lachmann, MA MB BChir MDFRCP, Julian D Gillmore, MBBS, MD PhD FRCP, Alexandra Pitchford, Louise Flanagan, PhD, Jamie B Oughton, MPhil, BSc, Shameem Mahmood, Sajitha Sachchithanantham, Sarah R Brown, PhD MSc, BSc, Ashutosh D Wechalekar, MBBS, MD FRCP, FRCPath, DM

Blood (2019) 134 (Supplement_1): 1890.

https://doi.org/10.1182/blood-2019-126567

Published: 2019

Journal Articles

The UK Experience of Renal Transplantation in AL Amyloidosis

Oliver C Cohen, MB BS, BSc, FRCPath, Faye Sharpley, MBBChir, MA, MRCP, MSc, Julian Gillmore, Helen Lachmann, Shameem Mahmood, Sajitha Sachchithanantham, Carol Whelan, Ana Martinez De Azcona Naharro, Marianna Fontana, Philip Hawkins, Ashutosh D. Wechalekar

Blood (2019) 134 (Supplement_1): 2206.

https://doi.org/10.1182/blood-2019-128443

Published: 2019

Journal Articles

A Novel Mass Spectrometry Method to Identify the Serum Monoclonal Light Chain Component and Infer Organ Involvement in Systemic Light Chain Amyloidosis

Faye Sharpley, Richa Manwani, MBBS, FRCPath, BSc, Shameem Mahmood, Sajitha Sachchithanantham, Helen Lachmann, Julian Gillmore, Carol Whelan, Philip Hawkins, Ashutosh D. Wechalekar

Blood (2018) 132 (Supplement 1): 4445.

https://doi.org/10.1182/blood-2018-99-114028

Published: 2018

Journal Articles

Improvement in Global Longitudinal Strain (GLS) Correlates with NT-Probnp Response in Patients with Cardiac Amyloidosis Treated on a Phase 1b Study of Anti-Amyloid Mab Cael-101

Divaya Bhutani, MD, Siyang Leng, MD, Andrew Eisenberger, MD, Mathew S. Maurer, MD, Sofia Shames, MD, Jeff Goldsmith, PhD, Suzanne Lentzsch, MD PhD

Blood (2018) 132 (Supplement 1): 958.

https://doi.org/10.1182/blood-2018-99-118464

Published: 2018

Journal Articles

Personalizing Amyloidosis Therapy with Real Time PET Imaging of Fibril-Reactive Monoclonal Antibody Cael-101

Jing Fu, PhD, Alan Solomon, MD, Patrick Carberry, PhD, John Castrillon, Jongho Kim, MD PhD, Suzanne Lentzsch, MD PhD, Akiva Mintz, MD PhD

Blood (2018) 132 (Supplement 1): 1003.

https://doi.org/10.1182/blood-2018-99-118177

Published: 2018

Journal Articles

VLITL is a major cross-β-sheet signal for fibrinogen Aα-chain frameshift variants

Cyrille Garnier, Fatma Briki, Brigitte Nedelec, Patrick Le Pogamp, Ahmet Dogan, Nathalie Rioux-Leclercq, Renan Goude, Caroline Beugnet, Laurent Martin, Marc Delpech, Frank Bridoux, Gilles Grateau, Jean Doucet, Philippe Derreumaux, Sophie Valleix

Blood (2017) 130 (25): 2799–2807.

https://doi.org/10.1182/blood-2017-07-796185

Published: 2017

Journal Articles

Rain (Renal AL Amyloid Involvement And NEOD001): A Multicenter, Randomized, Phase 2b Study of NEOD001 in Previously Treated Subjects With Systemic AL Amyloidosis and Persistent Renal Involvement

Cindy Varga, MD BSc, Angela Dispenzieri, MD, Morie A. Gertz, MD, Stacey A Goodman, MD MS, Kristen Hsu, Leslie Inker, MD, Heather Landau, MD, Nelson Leung, MD, Joseph R. Mikhael, MD, Taimur Sher, MD, Brendan M Weiss, MD, Sandy W. Wong, MD, Jeffrey A Zonder, MD, Raymond L. Comenzo, MD

Blood (2017) 130 (Supplement 1): 5437.

https://doi.org/10.1182/blood.V130.Suppl_1.5437.5437

Published: 2017

Journal Articles

Amyloid Fibril Formation of Immunoglobulin Light Chain Peptide from IHC-Negative AL Amyloidosis and Its Inhibition By Doxycycline and Epigallocatechin

Hiroyuki Hata, MD PhD, Toshiya Sugimoto, MT, Mitsuharu Ueda, MD, PhD, Nao Nishimura, MD, Shinya Endo, Yutaka Okuno, MD, PhD, Taro Yamashita, Konen Obayashi, MD, PhD, Masayoshi Tasaki, PhD, Eri Fujii, MT, Yuuki Inada, Misaki Kakoki, Yukio Ando, MD, PhD

Blood (2017) 130 (Supplement 1): 5331.

https://doi.org/10.1182/blood.V130.Suppl_1.5331.5331

Published: 2017

Journal Articles

Translocation (11;14) and Survival of Patients with AL Amyloidosis and Multiple Myeloma

Takao Yogo, Kanji Miyazaki, Kenshi Suzuki

Blood (2017) 130 (Supplement 1): 5333.

https://doi.org/10.1182/blood.V130.Suppl_1.5333.5333

Published: 2017

Journal Articles

Initial Report of a Serum Assay to Predict Amyloid Risk in Patients with Multiple Myeloma or Monoclonal Gammopathy of Undetermined Significance

Emily B. Martin, PhD, Angela Williams, MS, R. Eric Heidel, PhD, Ronald H. Lands, MD, Stephen J. Kennel, PhD, Angela Dispenzieri, MD, Jonathan S. Wall, PhD

Blood (2017) 130 (Supplement 1): 5371.

https://doi.org/10.1182/blood.V130.Suppl_1.5371.5371

Published: 2017

Journal Articles

Proteotoxicity in Cardiac Amyloidosis: Amyloidogenic Light Chains Affect the Levels of Iintracellular Proteins in Human Heart Cells

Esther Imperlini, PhD, Massimiliano Gnecchi, MD PhD, Paola Rognoni, PhD, Eduard Sabidò, PhD, Maria Chiara Ciuffreda, Giovanni Palladini, MDPhD, Guadalupe Espadas, Giuseppina Palladini, Stefania Orrù, PhD, Paolo Milani, MD PhD, Stefano Perlini, MD PhD, Francesco Salvatore, MD PhD, Giampaolo Merlini, MD, Francesca Lavatelli, MD PhD

Blood (2017) 130 (Supplement 1): 4393.

https://doi.org/10.1182/blood.V130.Suppl_1.4393.4393

Published: 2017

Journal Articles

Composite Organ and Hematologic Response Model Risk Stratifies Patients with Light Chain Amyloidosis

Blood (2017) 130 (Supplement 1): 3046.

https://doi.org/10.1182/blood.V130.Suppl_1.3046.3046

Published: 2017

Journal Articles

Final Analysis of the Phase 1a/b Study of Chimeric Fibril-Reactive Monoclonal Antibody 11-1F4 in Patients with Relapsed or Refractory AL Amyloidosis

Camille Vanessa Edwards, MBBS, BSc, Julia Gould, BA, Arielle L Langer, MD MPH, Markus Y Mapara, MD PhD, Jai Radhakrishnan, MD, Mathew S. Maurer, MD, Shahzad Raza, MD, John G. Mears, MD, Siyang Leng, MD, Jonathan S. Wall, PhD, Andrew Eisenberger, MD, Alan Solomon, MD, Suzanne Lentzsch, MD PhD

Blood (2017) 130 (Supplement 1): 509.

https://doi.org/10.1182/blood.V130.Suppl_1.509.509

Published: 2017

Journal Articles

Long-Term Outcomes of IMiD Based Trials in Patients with Immunoglobulin Light Chain Amyloidosis (AL): A Pooled Analysis

Blood (2017) 130 (Supplement 1): 1833.

https://doi.org/10.1182/blood.V130.Suppl_1.1833.1833

Published: 2017

Journal Articles

Biomarker-Based Screening of Organ Dysfunction in Patients with MGUS Allows Early Diagnosis of AL Amyloidosis

Giovanni Palladini, MDPhD, Marco Basset, MD, Paolo Milani, MD, Marzia Varettoni, MD, Silvia Mangiacavalli, MD, Francesca Russo, MD, Andrea Foli, MD, Alessandro Corso, MD, Giampaolo Merlini, MD

Blood (2017) 130 (Supplement 1): 1760.

https://doi.org/10.1182/blood.V130.Suppl_1.1760.1760

Published: 2017

NARROW

Primary Results from the Phase 3 Tourmaline-AL1 Trial of Ixazomib-Dexamethasone Versus Physician's Choice of Therapy in Patients (Pts) with Relapsed/Refractory Primary Systemic AL Amyloidosis (RRAL)

Localized Pulmonary Amyloidosis: A Single Institution Experience

Another Obesity Paradox: In Cardiac AL Amyloid a Higher BMI Is Associated with a Lower Rate of Cardiac Response

In Vitro and in Vivo Activity of Melflufen in Amyloidosis

β 2 -m - a Trigger for NLRP3 Inflammasome Activation within Macrophages Promoting Multiple Myeloma Cell Proliferation

A Phase 1 Study of Carfilzomib-Thalidomide-Dexamethasone in Patients with Relapsed/Refractory AL Amyloidosis - Catalyst Trial Results

The UK Experience of Renal Transplantation in AL Amyloidosis

A Novel Mass Spectrometry Method to Identify the Serum Monoclonal Light Chain Component and Infer Organ Involvement in Systemic Light Chain Amyloidosis

Improvement in Global Longitudinal Strain (GLS) Correlates with NT-Probnp Response in Patients with Cardiac Amyloidosis Treated on a Phase 1b Study of Anti-Amyloid Mab Cael-101

Personalizing Amyloidosis Therapy with Real Time PET Imaging of Fibril-Reactive Monoclonal Antibody Cael-101

VLITL is a major cross-β-sheet signal for fibrinogen Aα-chain frameshift variants

Rain (Renal AL Amyloid Involvement And NEOD001): A Multicenter, Randomized, Phase 2b Study of NEOD001 in Previously Treated Subjects With Systemic AL Amyloidosis and Persistent Renal Involvement

Amyloid Fibril Formation of Immunoglobulin Light Chain Peptide from IHC-Negative AL Amyloidosis and Its Inhibition By Doxycycline and Epigallocatechin

Translocation (11;14) and Survival of Patients with AL Amyloidosis and Multiple Myeloma

Initial Report of a Serum Assay to Predict Amyloid Risk in Patients with Multiple Myeloma or Monoclonal Gammopathy of Undetermined Significance

Proteotoxicity in Cardiac Amyloidosis: Amyloidogenic Light Chains Affect the Levels of Iintracellular Proteins in Human Heart Cells

Composite Organ and Hematologic Response Model Risk Stratifies Patients with Light Chain Amyloidosis

Final Analysis of the Phase 1a/b Study of Chimeric Fibril-Reactive Monoclonal Antibody 11-1F4 in Patients with Relapsed or Refractory AL Amyloidosis

Long-Term Outcomes of IMiD Based Trials in Patients with Immunoglobulin Light Chain Amyloidosis (AL): A Pooled Analysis

Biomarker-Based Screening of Organ Dysfunction in Patients with MGUS Allows Early Diagnosis of AL Amyloidosis

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only